HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2

PURPOSE: Dual blockade of HER2 with trastuzumab and lapatinib or pertuzumab has been shown to be superior to single-agent trastuzumab. However, a significant fraction of HER2-overexpressing (HER2+) breast cancers escape from these drug combinations. In this study, we sought to discover the mechanism...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Cancer Res
Glavni autori: Hanker, Ariella B., Garrett, Joan T., Estrada, Mónica Valeria, Moore, Preston D., Ericsson, Paula González, Koch, James P., Langley, Emma, Singh, Sharat, Kim, Phillip S., Frampton, Garrett M., Sanford, Eric, Owens, Philip, Becker, Jennifer, Groseclose, M. Reid, Castellino, Stephen, Joensuu, Heikki, Huober, Jens, Brase, Jan C., Majjaj, Samira, Brohée, Sylvain, Venet, David, Brown, David, Baselga, José, Piccart, Martine, Sotiriou, Christos, Arteaga, Carlos L.
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5540793/
https://ncbi.nlm.nih.gov/pubmed/28381415
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-2287
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items